A Phase 1 interventional study of losartan potassium (+) hydrochlorothiazide (HCTZ) and losartan potassium in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.
Among the 65 studies testing losartan in Hypertension, this one is the 37th largest by enrollment, is one of 5 that started in 2004, is one of 9 in phase 1, and was the 25th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Mayo Clinic · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 40+
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
Jing Liu · Sites in China
Ages 18–75
By country, each count listing its studies:
Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 7 · Phase 3 18 · Phase 4 26
First in 1990; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 65 interventional studies. Of the 47 that completed or were terminated, 20 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
26 studies in Hypertension by Organon & Co.: none open now, none under way, none of them phase 3. Of 26 finished, 15 (58%) have results posted.
Among the 26 studies in Hypertension by Organon & Co., this one is the 17th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2004, is one of 2 in phase 1, and was the 19th registered.
Organon & Co.’s Hypertension studies by the year they started, since 1995.
3 of the studies testing losartan in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
| NCT04715568University of California, San FranciscoSecondhand Tobacco Smoke and Cardiovascular Disease | 2026-12-31 |
| NCT07784621Huons Co., Ltd.A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults | 2027-02 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing losartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 26 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the bioequivalence of the losartan/hydrochlorothiazide (HCTZ) combination tablet and coadministration of losartan and hydrochlorothiazide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose losartan 100 mg/HCTZ 12.5 mg combination tablet
Drug: losartan potassium (+) hydrochlorothiazide (HCTZ)
Single dose losartan 100 mg tablet + HCTZ 12.5 mg capsule
Drug: losartan potassium · Drug: hydrochlorothiazide (HCTZ)
Drug page: Hydrochlorothiazide
Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
Single dose losartan 100 mg tablet in one of two treatment periods.
Also known as: COZAAR™
Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
Also known as: MICROZIDE™
Area Under the Curve (AUC(0 to Infinity)) of Losartan
Time frame: 0 to 36 Hours Post Dose
Peak Plasma Concentration (Cmax) for Losartan
Peak Plasma Concentration (Cmax), or maximal concentration of drug following dosing.
Time frame: 36 Hours Post Dose
Area Under the Curve (AUC(0 to Infinity)) of HCTZ
Plasma Area Under the Curve, a measure of drug exposure following dosing
Time frame: 0 to 30 Hours Post Dose
Peak Plasma Concentration (Cmax) of HCTZ Following Single Dose Administration of Losartan/HCTZ or Losartan and HCTZ
Peak Plasma Concentration (Cmax), or maximal concentration of drug following dosing
Time frame: 30 Hours Post Dose
| Milestone | Losartan-HCTZ Combination Tablet/Losartan Tablet +HCTZ Capsule | Losartan Tablet +HCTZ Capsule/Losartan-HCTZ Combination Tablet |
|---|---|---|
| Started | 38 | 39 |
| Completed | 38 | 38 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Losartan-HCTZ Combination Tablet/Losartan Tablet +HCTZ Capsule | Losartan Tablet +HCTZ Capsule/Losartan-HCTZ Combination Tablet |
|---|---|---|
| Started | 38 | 38 |
| Completed | 38 | 38 |
| Not completed | 0 | 0 |
| ng*hr/mL | Losartan-HCTZ Combination Tablet | Losartan Tablet + HCTZ Capsule |
|---|---|---|
| Area Under the Curve (AUC(0 to Infinity)) of Losartan | 1018.1 ± 382.5 | 1024.9 ± 354.6 |
Peak Plasma Concentration (Cmax), or maximal concentration of drug following dosing.
| ng/mL | Losartan-HCTZ Combination Tablet | Losartan Tablet + HCTZ Capsule |
|---|---|---|
| Peak Plasma Concentration (Cmax) for Losartan | 532.7 ± 334.9 | 637.9 ± 425.3 |
Plasma Area Under the Curve, a measure of drug exposure following dosing
| ng*hr/mL | Losartan-HCTZ Combination Tablet | Losartan Tablet + HCTZ Capsule |
|---|---|---|
| Area Under the Curve (AUC(0 to Infinity)) of HCTZ | 462.08 ± 144.72 | 499.90 ± 133.46 |
Peak Plasma Concentration (Cmax), or maximal concentration of drug following dosing
| ng/mL | Losartan-HCTZ Combination Tablet | Losartan Tablet + HCTZ Capsule |
|---|---|---|
| Peak Plasma Concentration (Cmax) of HCTZ Following Single Dose Administration of Losartan/HCTZ or Losartan and HCTZ | 76.15 ± 39.55 | 81.76 ± 31.05 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Losartan-HCTZ Combination Tablet/Losartan Tablet +HCTZ Capsule | — | 0/38 (0%) | 12/76 (15.8%) |
| Losartan Tablet +HCTZ Capsule/Losartan-HCTZ Combination Tablet | — | 0/39 (0%) | 10/77 (13%) |
| Event | Losartan-HCTZ Combination Tablet/Losartan Tablet +HCTZ Capsule | Losartan Tablet +HCTZ Capsule/Losartan-HCTZ Combination Tablet |
|---|---|---|
| HeadacheNervous system disorders | 8/76 | 6/77 |
| DizzinessNervous system disorders | 5/76 | 3/77 |
| VomitingGastrointestinal disorders | 1/76 | 1/77 |
| Alanine Aminotransferase IncreasedInvestigations | 1/76 | 0/77 |
| Aspartate Aminotransferase IncreasedInvestigations | 1/76 | 0/77 |
| NauseaGastrointestinal disorders | 0/76 | 1/77 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 33.87 (18 to 45) |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 46 |
| Male | 31 |
| Height(Centimeters) | All Participants |
|---|---|
| Mean | 166.81 (152 to 191) |
| Weight(kilograms) | All Participants |
|---|---|
| Mean | 73.01 (50 to 99.1) |
No study locations are listed for this record.
The record gives a start of Apr 2004, a primary completion of May 2004 and a completion of Jul 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 6 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Losartan